What's new? Log in Free sign up

Fate Therapeutics (FATE) News and press releases

Company Profile

News

From Benzinga Pro

GT Biopharma Issues Open Letter To Shareholders Detailing Recent Activities

News, Management

GT Biopharma, Inc. (the "Company" or "GTB") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer

5 Cheapest Health Care Stocks You Should Think About

Long Ideas, News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Trading Ideas

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Analyst Ratings for Fate Therapeutics

Analyst Ratings

Benzinga's Top Ratings Upgrades, Downgrades For January 24, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

HC Wainwright & Co. Downgrades Fate Therapeutics to Neutral, Lowers Price Target to $7

News, Downgrades, Price Target, Analyst Ratings

HC Wainwright & Co. analyst Robert Burns downgrades Fate Therapeutics (NASDAQ:FATE) from Buy to Neutral and lowers the price target from $115 to $7.

5 Health Care Stocks That Are Diving - And May Rally

Long Ideas, News, Penny Stocks, Health Care, Small Cap, Pre-Market Outlook, Markets, Trading Ideas, General

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Over $10 Million Bet On DiamondHead Holdings? Check Out These 4 Stocks Insiders Are Buying

News, Small Cap, Insider Trades, Pre-Market Outlook, Markets, Trading Ideas

Although US stocks closed higher on Friday, there were a few notable insider trades.

Top 5 Health Care Stocks That May Surge

Long Ideas, News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Trading Ideas

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

How Is The Market Feeling About Fate Therapeutics?

Short Sellers, Short Ideas, Trading Ideas

Fate Therapeutics's (NASDAQ:FATE) short percent of float has fallen 4.62% since its last report. The company recently reported that it has 20.24 million shares sold short, which is 27.85% of all regular shares that are available for trading.

Goldman Sachs Maintains Sell on Fate Therapeutics, Lowers Price Target to $4

News, Price Target, Analyst Ratings

Goldman Sachs analyst Andrea Tan maintains Fate Therapeutics (NASDAQ:FATE) with a Sell and lowers the price target from $10 to $4.

Dow Jumps 700 Points; S&P 500 Rises Over 2%

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday.

Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.

12 Health Care Stocks Moving In Friday's Intraday Session

Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge

Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday.

Stocks That Hit 52-Week Lows On Friday

During Friday's trading, 71 companies set new 52-week lows.

Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday

News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas

U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording losses in today’s session.

Fate Therapeutics Ends Collaboration Deal With Janssen, Cuts Staff

Biotech, Large Cap, News, Penny Stocks, Health Care, Contracts, Small Cap, Movers, Trading Ideas, General

Dow Rises Over 300 Points; US Adds 223,000 Jobs In December

Earnings, News, Penny Stocks, Eurozone, Small Cap, Global, Intraday Update, Markets

U.S. stocks traded higher this morning, with the Dow Jones gaining more than 300 points on Friday.

Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023

Upgrades, Downgrades, Initiation, Intraday Update, Analyst Ratings

Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $8

News, Price Target, Analyst Ratings

Morgan Stanley analyst Michael Ulz maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $35 to $8.

Press releases

From Benzinga Pro

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm's Attorneys, Securities Class Action Filed

News, Legal, Press Releases

SAN FRANCISCO, Feb. 06, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ:FATE) investors who suffered significant losses to submit your losses now. Class Period: Apr. 2, 2020 – Jan. 5,

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

NEW YORK, NY / ACCESSWIRE / February 6, 2023 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ:FATE) between April 2, 2020 and January 5,

YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

NEW YORK, NY / ACCESSWIRE / February 6, 2023 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of

Fate Class Action: Levi & Korsinsky Reminds Fate Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 22, 2023 - FATE

New York, New York--(Newsfile Corp. - February 6, 2023) - Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. (NASDAQ:FATE) ("Fate" or the "Company") of a class action securities lawsuit.The

ROSEN, A LONGSTANDING LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

NEW YORK, Feb. 5, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – FATE

News, Legal, Press Releases

NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. ("Fate" or the "Company")

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FATE

NEW YORK, NY / ACCESSWIRE / February 4, 2023 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ:FATE) between April 2, 2020 and January 5,

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bioventus, ESS, IBM, and FATE and Encourages Investors to Contact the Firm

News, Legal, Press Releases

NEW YORK, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of

FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm's Attorneys, Securities Fraud Lawsuit Pending

SAN FRANCISCO, CA / AACCESSWIRE / February 3, 2023 / Hagens Berman urges Fate Therapeutics, Inc. (NASDAQ:FATE) investors who suffered significant losses to submit your losses now.Class Period: Apr. 2, 2020 - Jan. 5,

DEADLINE ALERT for FATE, SHC, ARBK, and EYE: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

News, Legal, Press Releases

LOS ANGELES, Feb. 03, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

NEW YORK, NY / ACCESSWIRE / February 3, 2023 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - FATE

New York, New York--(Newsfile Corp. - February 3, 2023) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ:FATE) between April 2, 2020

FATE SHAREHOLDER ALERT: Jakubowitz Law Reminds Fate Shareholders of a Lead Plaintiff Deadline of March 22, 2023

NEW YORK, Feb. 3, 2023 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Fate Therapeutics, Inc. (NASDAQ:FATE). To receive updates on the

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Fate Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - FATE

New York, New York--(Newsfile Corp. - February 2, 2023) - Pomerantz LLP announces that a class action lawsuit has been filed against certain officers and directors of Fate Therapeutics, Inc. ("Fate" or the "Company")

Fate Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 22, 2023 to Discuss Your Rights - FATE

New York, New York--(Newsfile Corp. - February 2, 2023) - Levi & Korsinsky, LLP notifies investors in Fate Therapeutics, Inc. ("Fate" or the "Company") (NASDAQ:FATE) of a class action securities lawsuit.The lawsuit

Fate Therapeutics, Inc. (FATE) Shareholder Notice: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Against Fate Therapeutics, Inc.

The Class: Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired shares of Fate Therapeutics, Inc. (NASDAQ:FATE) common stock between April

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Fate Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – FATE

NEW YORK, NY / ACCESSWIRE / February 2, 2023 / Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Fate Therapeutics, Inc. (NASDAQ:FATE) between April 2, 2020 and January 5, 2023,

CLASS ACTION UPDATE for FXLV, NBEVQ and FATE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / February 2, 2023 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested

YMAB, BVS & FATE Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors of Deadlines and to Actively Participate

News, Legal, Press Releases

NEW YORK, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies.

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company" or "GTB") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the